Eye drop showdown: which cyclosporine works best for dry eyes?
NCT ID NCT07368595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two approved cyclosporine eye drops—Vevye (0.1%) and a generic (0.05%)—in 60 adults with dry eye disease. Over 8 weeks, researchers will measure changes in goblet cells, which produce mucus to keep eyes moist. Participants use drops daily and visit the clinic every two weeks for exams.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclosporine eye drops (Vevye 0.1% and generic 0.05%)
What this could lead to
If successful, this could show which cyclosporine formulation better restores mucus-producing cells in the eye, potentially improving dry eye treatment.
What could go wrong
This is a small, early-phase trial (60 people) comparing two already-approved drugs, so it won't produce a new treatment. Results may not apply to all dry eye patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••